Medline (NASDAQ:MDLN) Sees Strong Trading Volume on Analyst Upgrade

Shares of Medline (NASDAQ:MDLN – Get Free Report) saw an uptick in trading volume on Wednesday after Zacks Research upgraded the stock from a strong sell rating to a hold rating. 17,499,610 shares traded hands during trading, an increase of 124% from the average daily volume of 7,795,192 shares. The stock last traded at $38.8150 and had previously closed at $37.68.

A number of other research firms have also weighed in on MDLN. William Blair reaffirmed an “outperform” rating on shares of Medline in a report on Wednesday, September 23rd. JPMorgan Chase & Co. decreased their target price on Medline from $53.00 to $46.00 and set an “overweight” rating for the company in a report on Wednesday, August 12th. Weiss Ratings upgraded shares of Medline from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday, November 9th. BTIG Research reiterated a “buy” rating and issued a $55.00 target price on shares of Medline in a research note on Thursday, November 5th. Finally, Stifel Nicolaus reduced their price objective on Medline from $50.00 to $45.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Twenty-three equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Medline presently has an average rating of “Moderate Buy” and an average target price of $46.08.

View Our Latest Research Report on MDLN

Insider Activity

In other news, major shareholder Private Ltd Gic sold 2,088,987 shares of the company’s stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $35.05, for a total value of $73,218,994.35. Following the transaction, the insider directly owned 16,453,806 shares in the company, valued at approximately $576,705,900.30. This represents a 11.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have sold 6,348,676 shares of company stock worth $224,525,137 over the last ninety days. 0.81% of the stock is currently owned by insiders.

Top Medline Stories

These are some of the MDLN stories that stood out recently:

  • Positive Sentiment: Several recent valuation articles argue Medline may be undervalued, estimating upside of about 19% to 33%; a separate report says analysts raised fair-value estimates. These are valuation opinions, not guarantees of future performance. Article Article Article
  • Neutral Sentiment: Unusually high call-option trading was reported, but options activity alone does not establish a lasting bullish outlook. Medline also introduced right-sized packaging at two distribution centers, a potential operational-efficiency measure with no disclosed financial impact. Company announcement
  • Negative Sentiment: Medline has reported additional deaths in connection with its electric-bed recall, raising potential product-liability and reputational concerns. Separately, a law firm announced a securities-fraud investigation; this is an investigation announcement, not a finding of wrongdoing. Article Investigation announcement

Institutional Investors Weigh In On Medline

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC lifted its position in shares of Medline by 68.3% in the second quarter. GAMMA Investing LLC now owns 626 shares of the company’s stock valued at $25,000 after acquiring an additional 254 shares in the last quarter. Reyes Financial Architecture Inc. acquired a new position in Medline during the third quarter worth $30,000. NewEdge Advisors LLC boosted its stake in shares of Medline by 100.0% in the second quarter. NewEdge Advisors LLC now owns 950 shares of the company’s stock valued at $37,000 after purchasing an additional 475 shares during the period. Allworth Financial LP boosted its holdings in Medline by 86.2% in the second quarter. Allworth Financial LP now owns 1,052 shares of the company’s stock valued at $41,000 after purchasing an additional 487 shares during the period. Finally, Flputnam Investment Management Co. acquired a new position in Medline during the 3rd quarter worth approximately $43,000.

Medline Trading Down 3.4%

The business has a fifty day moving average price of $35.60 and a 200 day moving average price of $39.25. The company has a current ratio of 4.04, a quick ratio of 2.51 and a debt-to-equity ratio of 0.65. The firm has a market cap of $49.77 billion and a PE ratio of 86.00.

Medline (NASDAQ:MDLN – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.32 by $0.12. Medline had a net margin of 1.84% and a return on equity of 8.21%. The firm had revenue of $7.86 billion during the quarter. Analysts forecast that Medline will post 1.58 EPS for the current year.

Medline Company Profile

(Get Free Report)

Medline is a healthcare products manufacturer and distributor serving providers across the care continuum. Its customers include hospitals, surgery centers, physician practices, long-term care facilities and home-care organizations. The company offers a broad range of medical and surgical supplies, including products for infection prevention, wound care and patient care, as well as apparel and equipment. Medline also provides supply-chain and logistics services to healthcare organizations. Founded in 1966, Medline is headquartered in Northfield, Illinois, and serves customers in the United States and internationally.

Further Reading

Receive News & Ratings for Medline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medline and related companies with MarketBeat.com's FREE daily email newsletter.